Journal of AIDS & Clinical Research

Baerbel Peetroons

Publications

• Research Article
  Budget Impact Analysis Highlighting the Cost-Saving Potential of Generic Tenofovir Disoproxil Based Antiretroviral Therapy in Comparison with Tenofovir Alafenamide Based Treatment Regimens in the German Healthcare System
  Author(s): Matthias Stoll, Phoebe Balkin, Joachim Goldbach, Philipp Weber, Baerbel Peetroons and Sameer B GokhaleMatthias Stoll, Phoebe Balkin, Joachim Goldbach, Philipp Weber, Baerbel Peetroons and Sameer B Gokhale
  
  Objective: The fixed dose combination (FDC) of tenofovir disoproxil (TD) fumarate/emtricitabine (FTC) has been the most widely used backbone treatment for HIV until recently. In 2016, tenofovir alafenamide (TAF)/FTC became available as FDC, which promises superior renal and bone safety. However, in November 2016, the German Federal Joint Committee concluded that there is no additional benefit to the use of TAF versus TD fumarate. The decision of choosing TD or TAF in FDC with FTC is of economic impact as cost-saving generics (Gx-TD/FTC) became available in Germany in August 2017.Methods: A budget impact analysis (BIA) was conducted to estimate the impact of Gx-TD/FTC on the German healthcare system for 5-years. The BIA compared a theoretical setting with and without introduction of Gx-TD/FTC; calculating the respective costs for antiretroviral t.. Read More»
  DOI: 10.4172/2155-6113.1000754

  Abstract PDF